174 related articles for article (PubMed ID: 21737627)
1. Associations of HSP90 client proteins in human breast cancer.
Shipp C; Watson K; Jones GL
Anticancer Res; 2011 Jun; 31(6):2095-101. PubMed ID: 21737627
[TBL] [Abstract][Full Text] [Related]
2. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
[TBL] [Abstract][Full Text] [Related]
3. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
4. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis.
Zhang MH; Lee JS; Kim HJ; Jin DI; Kim JI; Lee KJ; Seo JS
Mol Cell Biochem; 2006 Jan; 281(1-2):111-21. PubMed ID: 16328963
[TBL] [Abstract][Full Text] [Related]
5. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
Taiyab A; Rao ChM
Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
[TBL] [Abstract][Full Text] [Related]
6. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
7. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
8. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
9. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
[TBL] [Abstract][Full Text] [Related]
10. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
11. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
[TBL] [Abstract][Full Text] [Related]
12. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.
Mahanta S; Pilla S; Paul S
Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
Yun BG; Matts RL
Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
De Mattos-Arruda L; Cortes J
Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Kang SA; Cho HS; Yoon JB; Chung IK; Lee ST
Biochem J; 2012 Oct; 447(2):313-20. PubMed ID: 22849407
[TBL] [Abstract][Full Text] [Related]
17. Geldanamycin administration reduces the amount of primordial germ cells in the mouse embryo.
Lejong M; Choa-Duterre M; Vanmuylder N; Louryan S
Morphologie; 2018 Sep; 102(338):219-224. PubMed ID: 29807855
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: targeting hsp90--who benefits and who does not.
Scaltriti M; Dawood S; Cortes J
Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860
[TBL] [Abstract][Full Text] [Related]
19. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]